NVDA
52
5
LOW
42
14
CLX
65
2
MCO
67
3
HUM
25
4
WHR
61
3
GME
61
2
ITW
45
2
EMR
57
7
SLG
37
6
KHC
11
2
CNP
59
17
WMT
68
-2
INTU
54
2
MDLZ
28
2
CINF
24
-8
EXPE
83
8
EFX
43
3
DOW
47
4
SYF
78
7
NVDA
52
5
LOW
42
14
CLX
65
2
MCO
67
3
HUM
25
4
WHR
61
3
GME
61
2
ITW
45
2
EMR
57
7
SLG
37
6
KHC
11
2
CNP
59
17
WMT
68
-2
INTU
54
2
MDLZ
28
2
CINF
24
-8
EXPE
83
8
EFX
43
3
DOW
47
4
SYF
78
7
Financhill
Back

Blueprint Medicines 10K Form

Sell
40

BPMC
Blueprint Medicines

Last Price:
$90.24
Seasonality Move:
2.18%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-10-26 10Q BPMC/Blueprint Medicines Quarterly
2023-08-02 10Q BPMC/Blueprint Medicines Quarterly
2023-05-04 10Q BPMC/Blueprint Medicines Quarterly
2022-11-01 10Q BPMC/Blueprint Medicines Quarterly
2022-08-02 10Q BPMC/Blueprint Medicines Quarterly
2022-05-03 10Q BPMC/Blueprint Medicines Quarterly

Receive BPMC News And Ratings

See the #1 stock for the next 7 days that we like better than BPMC

BPMC Financial Statistics

Sales & Book Value

Annual Sales: $249.4M
Cash Flow: $-13.7M
Price / Cash Flow: 0
Annual Sales: $4.94
Price / Book: 18.3

Profitability

EPS (TTM): -2.11000
Net Income (TTM): $-128.1M
Gross Margin: $240.8M
Return on Equity: -50.13%
Return on Assets: -11.44%

Blueprint Medicines Earnings Forecast

Key Blueprint Medicines Financial Ratios

  • The Gross Profit Margin over the past 9 years for BPMC is 96.58%.
  • The Selling, General & Administrative Expenses for BPMC have been equal to 118.35% of Gross Profit Margin.
  • The Research & Development expenses have been 171.51% of Revenue.
  • The Interest Expense is -0.03% of Operating Income.
  • The Net Earning history of BPMC is -203.30% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

Blueprint Medicines Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BPMC
CUSIP: 09627Y
Website: blueprintmedicines.com

Debt

Debt-to-Equity Ratio: 1.23
Current Ratio: 3.32
Quick Ratio: 3.1

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BPMC Technical Analysis vs Fundamental Analysis

Sell
40
Blueprint Medicines (BPMC) is a Sell

Is Blueprint Medicines a Buy or a Sell?